Analyst
BNP Paribas
Equibles does not estimate personal net worth.
Navantai is recorded as Analyst at BNP Paribas. Navantai has spoken on 3 earnings calls across 3 companies, most recently for Evolus, Inc. on November 4, 2026. Those appearances were for Evolus, Inc. (EOLS), Medline Inc. (MDLN) and Zoetis Inc. (ZTS). The companies whose calls Navantai spoke on are classified in the Healthcare sector.
“Can you maybe start how are toxins and fillers trending in that seasonally high Q4? And then if you have any initial comments on the toxin and fillers market for 2027, and then if you could also quantify the meaningful share gain in fillers, if possible.”
“I just wanted to clarify a previous point on the global action plan. I mean, first, is there any other product at risk of warning letters and recalls, potentially?”
“Do you still expect approval of the long-acting OA pain this year? and how is the dialogue with the FDA and or the EC? And we know that the long-acting will be marketed under a different brand name than Librella and Better Dosing and COGS.”
BNP Paribas
Analyst
Transcript header (unverified)
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
MDLN
Medical Instruments & Supplies · Healthcare
ZTS
Drug Manufacturers - Specialty & Generic · Healthcare
